Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adc Therapeutics Sa (NY: ADCT )

2.030 +0.040 (+2.01%)
Streaming Delayed Price Updated: 10:55 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adc Therapeutics Sa

< Previous 1 2 3 4 5 6 7 8 Next >
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces CEO Transition
From ADC Therapeutics SA
Via Business Wire
Earnings Outlook For ADC Therapeutics
ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that ADC... 
Via Benzinga
ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
Recap: ADC Therapeutics Q4 Earnings
ADC Therapeutics (NYSE:ADCT) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
How To Attend ADC Therapeutics Q1 2022 Earnings Conference Call
ADC Therapeutics (NYSE:ADCT) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend ADC Therapeutics (ADCT) Conference Call Follow this link to... 
Via Benzinga
ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021
From ADC Therapeutics SA
Via Business Wire
Cantor Fitzgerald Cuts ADC Therapeutics Price Target On 'Repositioned Zynlonta Pipeline Strategy'
Following Q4 FY21 results, Cantor Fitzgerald has lowered the price target on ADC Therapeutics SA (NASDAQ: ADCT) to $26 from $45 and keeps an Overweight rating... 
Via Benzinga
Earnings Preview For ADC Therapeutics
ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report
From ADC Therapeutics SA
Via Business Wire
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in Guggenheim Oncology Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022
From ADC Therapeutics
Via Business Wire
ADC Therapeutics, Mitsubishi Tanabe Ink Zynlonta Licensing Pact In Japan
ADC Therapeutics SA (NYSE: ADCT) has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize... 
Via Benzinga
52 Biggest Movers From Friday
Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its... 
Via Benzinga
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
From ADC Therapeutics SA
Via Business Wire
30 Stocks Moving In Friday's Mid-Day Session
Gainers ATI Physical Therapy, Inc. (NYSE: ATIP) shares gained 25.2% to $3.8050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.50 to $5.... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE: 
Via Benzinga
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
From ADC Therapeutics
Via Business Wire
ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
From ADC Therapeutics SA
Via Business Wire
71 Biggest Movers From Yesterday
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales... 
Via Benzinga
ADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript
ADCT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
From ADC Therapeutics SA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.